POG 9575 TOPOTECAN FOR REFRACTORY LEUKEMIA

POG 9575 拓扑替康治疗难治性白血病

• 批准号: 6265148
• 负责人: FAITH H KUNG
• 金额: $ 1.15万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265148
• 关键词: clinical research; cytotoxicity; drug administration rate /duration; drug screening /evaluation; drug tolerance; human subject; human therapy evaluation; injection /infusion; leukemia; neoplasm /cancer chemotherapy; pharmacokinetics; topotecan

Determine qualitative and quantitative toxicity of topotecan when administered by 30 minute influsions for 7-12 consecutive days every 3 weeks. Establish maximum tolerated dose, characterize pharmacokinetics and observe anti-tumor effects.

每3周连续7-12天通过30分钟的炎症给药时，确定拓扑替康的定性和定量毒性。 建立最大耐受剂量，表征药代动力学并观察抗肿瘤作用。